Sustained wash-resistant receptor activation responses of GPR119 agonists

European Journal of Pharmacology

Volumn 762, Issue , 2015, Pages 430-442

  Hothersall, J Daniel ^a   Bussey, Charlotte E ^a   Brown, Alastair J ^a,b   Scott, James S ^a   Dale, Ian ^a   Rawlins, Philip ^a  

^a ASTRAZENECA   (United Kingdom)

^b Heptares Therapeutics Ltd   (United Kingdom)

Author keywords

Agonist; Binding kinetics; Desensitization; GPR119; Membrane deposition; Sustained signalling

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; AR 231453; ARN II; AZ 1; AZ 2; AZ 3; CYCLIC AMP; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 119; G PROTEIN COUPLED RECEPTOR 119 AGONIST; GLUCAGON LIKE PEPTIDE 1; GSK 1292263; MBX 2982; N OLEOYLETHANOLAMINE; UNCLASSIFIED DRUG; GPR119 PROTEIN, HUMAN;

ARTICLE; BINDING KINETICS; CAMP ASSAY; CONTROLLED STUDY; HEK293 CELL LINE; HUMAN; HUMAN CELL; LONG TERM EXPOSURE; MEMBRANE BINDING; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; AGONISTS; CELL MEMBRANE; DRUG EFFECTS; KINETICS; METABOLISM;

CELL MEMBRANE; CYCLIC AMP; HEK293 CELLS; HUMANS; KINETICS; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84933038407     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2015.06.031     Document Type: Article

References (38)

1. G.P. Anderson, A. Linden, and K.F. Rabe Why are long-acting beta-adrenoceptor agonists long-acting? Eur. Respir. J. 7 1994 569 578
2. K.V. Andreassen, S.T. Hjuler, S.G. Furness, P.M. Sexton, A. Christopoulos, O. Nosjean, M.A. Karsdal, and K. Henriksen Prolonged calcitonin receptor signaling by salmon, but not human calcitonin, reveals ligand bias PLoS One 9 2014 e92042
3. K.J. Brocklehurst, A. Broo, R.J. Butlin, H.S. Brown, D.S. Clarke, O. Davidsson, K. Goldberg, S.D. Groombridge, E.E. Kelly, A. Leach, D. McKerrecher, C. O'Donnell, S. Poucher, P. Schofield, J.S. Scott, J. Teague, L. Westgate, and M.J. Wood Discovery, optimisation and in vivo evaluation of novel GPR119 agonists Bioorg. Med. Chem. Lett. 21 2011 7310 7316
4. D. Calebiro, V.O. Nikolaev, M.C. Gagliani, F.T. de, C. Dees, C. Tacchetti, L. Persani, and M.J. Lohse Persistent cAMP-signals triggered by internalized G-protein-coupled receptors PLoS Biol. 7 2009 e1000172
5. G.E. Callander, W.G. Thomas, and R.A. Bathgate Prolonged RXFP1 and RXFP2 signaling can be explained by poor internalization and a lack of beta-arrestin recruitment Am. J. Physiol.: Cell Physiol. 296 2009 C1058 C1066
6. Z.L. Chu, C. Carroll, J. Alfonso, V. Gutierrez, H. He, A. Lucman, M. Pedraza, H. Mondala, H. Gao, D. Bagnol, R. Chen, R.M. Jones, D.P. Behan, and J. Leonard A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like peptide-1 and glucose-dependent insulinotropic peptide release Endocrinology 149 2008 2038 2047
7. Z.L. Chu, R.M. Jones, H. He, C. Carroll, V. Gutierrez, A. Lucman, M. Moloney, H. Gao, H. Mondala, D. Bagnol, D. Unett, Y. Liang, K. Demarest, G. Semple, D.P. Behan, and J. Leonard A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release Endocrinology 148 2007 2601 2609
8. R.A. Copeland, D.L. Pompliano, and T.D. Meek Drug-target residence time and its implications for lead optimization Nat. Rev. Drug Discov. 5 2006 730 739
9. L.M. Cornall, M.L. Mathai, D.H. Hryciw, and A.J. McAinch Is GPR119 agonism an appropriate treatment modality for the safe amelioration of metabolic diseases? Expert Opin. Investig. Drugs 22 2013 487 498
10. T. Dean, J.P. Vilardaga, J.T., Jr Potts, and T.J. Gardella Altered selectivity of parathyroid hormone (PTH) and PTH-related protein (PTHrP) for distinct conformations of the PTH/PTHrP receptor Mol. Endocrinol. 22 2008 156 166
11. M.T. Drake, S.K. Shenoy, and R.J. Lefkowitz Trafficking of G protein-coupled receptors Circ. Res. 99 2006 570 582
12. S. Ferrandon, T.N. Feinstein, M. Castro, B. Wang, R. Bouley, J.T. Potts, T.J. Gardella, and J.P. Vilardaga Sustained cyclic AMP production by parathyroid hormone receptor endocytosis Nat. Chem. Biol. 5 2009 734 742
13. D. Guo, J.M. Hillger, A.P. IJzerman, and L.H. Heitman Drug-target residence time-a case for g protein-coupled receptors Med. Res. Rev. 34 2014 856 892
14. K.B. Hansen, M.M. Rosenkilde, F.K. Knop, N. Wellner, T.A. Diep, J.F. Rehfeld, U.B. Andersen, J.J. Holst, and H.S. Hansen 2-Oleoyl glycerol is a GPR119 agonist and signals GLP-1 release in humans J. Clin. Endocrinol. Metab. 96 2011 E1409 E1417
15. C. Haskell-Luevano, H. Miwa, C. Dickinson, M.E. Hadley, V.J. Hruby, T. Yamada, and I. Gantz Characterizations of the unusual dissociation properties of melanotropin peptides from the melanocortin receptor, hMC1R J. Med. Chem. 39 1996 432 435
16. J. Jakubik, S. Tucek, and E.E. El-Fakahany Allosteric modulation by persistent binding of xanomeline of the interaction of competitive ligands with the M1 muscarinic acetylcholine receptor J. Pharmacol. Exp. Ther. 301 2002 1033 1041
17. D.D. Jensen, C.B. Godfrey, C. Niklas, M. Canals, M. Kocan, D.P. Poole, J.E. Murphy, F. Alemi, G.S. Cottrell, C. Korbmacher, N.A. Lambert, N.W. Bunnett, and C.U. Corvera The bile acid receptor TGR5 does not interact with beta-arrestins or traffic to endosomes but transmits sustained signals from plasma membrane rafts J. Biol. Chem. 288 2013 22942 22960
18. S.U. Kang GPR119 agonists: a promising approach for T2DM treatment? A SWOT analysis of GPR119 Drug Discov. Today 18 2013 1309 1315
19. E. Kelly, C.P. Bailey, and G. Henderson Agonist-selective mechanisms of GPCR desensitization Br. J. Pharmacol 153 Suppl 1 2008 S379 S388
20. P. Kumar, A. Kumar, and Z.H. Song Structure-activity relationships of fatty acid amide ligands in activating and desensitizing G protein-coupled receptor 119 Eur. J. Pharmacol. 723 2014 465 472
21. H. Lan, H.V. Lin, C.F. Wang, M.J. Wright, S. Xu, L. Kang, K. Juhl, J.A. Hedrick, and T.J. Kowalski Agonists at GPR119 mediate secretion of GLP-1 from mouse enteroendocrine cells through glucose-independent pathways Br. J. Pharmacol. 165 2012 2799 2807
22. H. Lan, G. Vassileva, A. Corona, L. Liu, H. Baker, A. Golovko, S.J. Abbondanzo, W. Hu, S. Yang, Y. Ning, R.A. Del Vecchio, F. Poulet, M. Laverty, E.L. Gustafson, J.A. Hedrick, and T.J. Kowalski GPR119 is required for physiological regulation of glucagon-like peptide-1 secretion but not for metabolic homeostasis J. Endocrinol. 201 2009 219 230
23. L.M. Lauffer, R. Iakoubov, and P.L. Brubaker GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell Diabetes 58 2009 1058 1066
24. F. Mullershausen, F. Zecri, C. Cetin, A. Billich, D. Guerini, and K. Seuwen Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors Nat. Chem. Biol. 5 2009 428 434
25. T. Ohishi, and S. Yoshida The therapeutic potential of GPR119 agonists for type 2 diabetes Expert Opin. Investig. Drugs 21 2012 321 328
26. M. Okazaki, S. Ferrandon, J.P. Vilardaga, M.L. Bouxsein, J.T. Potts Jr., and T.J. Gardella Prolonged signaling at the parathyroid hormone receptor by peptide ligands targeted to a specific receptor conformation Proc. Natl. Acad. Sci. USA 105 2008 16525 16530
27. J.S. Scott, A.M. Birch, K.J. Brocklehurst, A. Broo, H.S. Brown, R.J. Butlin, D.S. Clarke, O. Davidsson, A. Ertan, K. Goldberg, S.D. Groombridge, J.A. Hudson, D. Laber, A.G. Leach, P.A. MacFaul, D. McKerrecher, A. Pickup, P. Schofield, P.H. Svensson, P. Sorme, and J. Teague Use of small-molecule crystal structures to address solubility in a novel series of G protein coupled receptor 119 agonists: optimization of a lead and in vivo evaluation J. Med. Chem. 55 2012 5361 5379
28. J.S. Scott, K.J. Brocklehurst, H.S. Brown, D.S. Clarke, H. Coe, S.D. Groombridge, D. Laber, P.A. MacFaul, D. McKerrecher, and P. Schofield Conformational restriction in a series of GPR119 agonists: differences in pharmacology between mouse and human Bioorg. Med. Chem. Lett. 23 2013 3175 3179
29. G. Semple, B. Fioravanti, G. Pereira, I. Calderon, J. Uy, K. Choi, Y. Xiong, A. Ren, M. Morgan, V. Dave, W. Thomsen, D.J. Unett, C. Xing, S. Bossie, C. Carroll, Z.L. Chu, A.J. Grottick, E.K. Hauser, J. Leonard, and R.M. Jones Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119 J. Med. Chem. 51 2008 5172 5175
30. G. Semple, J. Lehmann, A. Wong, A. Ren, M. Bruce, Y.J. Shin, C.R. Sage, M. Morgan, W.C. Chen, K. Sebring, Z.L. Chu, J.N. Leonard, H. Al-Shamma, A.J. Grottick, F. Du, Y. Liang, K. Demarest, and R.M. Jones Discovery of a second generation agonist of the orphan G-protein coupled receptor GPR119 with an improved profile Bioorg. Med. Chem. Lett. 22 2012 1750 1755
31. G. Semple, A. Ren, B. Fioravanti, G. Pereira, I. Calderon, K. Choi, Y. Xiong, Y.J. Shin, T. Gharbaoui, C.R. Sage, M. Morgan, C. Xing, Z.L. Chu, J.N. Leonard, A.J. Grottick, H. Al-Shamma, Y. Liang, K.T. Demarest, and R.M. Jones Discovery of fused bicyclic agonists of the orphan G-protein coupled receptor GPR119 with in vivo activity in rodent models of glucose control Bioorg. Med. Chem. Lett. 21 2011 3134 3141
32. T. Soga, T. Ohishi, T. Matsui, T. Saito, M. Matsumoto, J. Takasaki, S. Matsumoto, M. Kamohara, H. Hiyama, S. Yoshida, K. Momose, Y. Ueda, H. Matsushime, M. Kobori, and K. Furuichi Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor Biochem. Biophys. Res. Commun. 326 2005 744 751
33. S.K. Syed, H.H. Bui, L.S. Beavers, T.B. Farb, J. Ficorilli, A.K. Chesterfield, M.S. Kuo, K. Bokvist, D.G. Barrett, and A.M. Efanov Regulation of GPR119 receptor activity with endocannabinoid-like lipids Am. J. Physiol. Endocrinol. Metab. 303 2012 E1469 E1478
34. A. Szczuka, M. Wennerberg, A. Packeu, and G. Vauquelin Molecular mechanisms for the persistent bronchodilatory effect of the beta 2-adrenoceptor agonist salmeterol Br. J. Pharmacol. 158 2009 183 194
35. A. Teschemacher, and H. Lemoine Kinetic analysis of drug-receptor interactions of long-acting beta2 sympathomimetics in isolated receptor membranes: evidence against prolonged effects of salmeterol and formoterol on receptor-coupled adenylyl cyclase J. Pharmacol. Exp. Ther. 288 1999 1084 1092
36. G. Vauquelin, and S.J. Charlton Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action Br. J. Pharmacol. 161 2010 488 508
37. G.B. Willars, A. Heding, M. Vrecl, R. Sellar, M. Blomenrohr, S.R. Nahorski, and K.A. Eidne Lack of a C-terminal tail in the mammalian gonadotropin-releasing hormone receptor confers resistance to agonist-dependent phosphorylation and rapid desensitization J. Biol. Chem. 274 1999 30146 30153
38. S.Y. Zhang, J. Li, and X. Xie Discovery and characterization of novel smallmolecule agonists of G protein-coupled receptor 119 Acta Pharmacol. Sin. 35 2014 540 548